Potential Alzheimer’s blood biomarkers may monitor pathology of disease

Written by Vivian Xie

A team of researchers from the Swiss Federal Laboratories for Materials Science and Technology (Empa, Dübendorf, Switzerland) and the Cantonal Hospital of St. Gallen (St. Gallen, Switzerland) have reported on potential Alzheimer’s blood biomarkers, analyzed utilizing atomic force microscopy (AFM), that may lead to the development of a blood test for the diagnosis and monitoring of the neurodegenerative disease. In the effort to understand the molecular pathogenesis of Alzheimer’s disease, deciphering the role of molecules such as beta-amyloid peptides and tau proteins associated with the disease would be a major step forward. Current techniques that quantify the two proteins in...

To view this content, please register now for access

It's completely free